Biotech analyst Adam Feurstein weighs in on the 10.5% premarket run in shares of BioSante...

|By:, SA News Editor

Biotech analyst Adam Feurstein weighs in on the 10.5% premarket run in shares of BioSante Pharmaceuticals (BPAX) tied to the firm's announcement on its GVAX vaccine - calling out that the firm is "hyping" previously released data.